Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Aspyrian Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3051)・商品コード:DATA904C3051
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:22
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a clinical stage biotechnology company that develops first-in-class precision targeted cancer drugs for the treatment of solid tumors. The company harnesses the Photoimmunotherapy (PIT) platform to develop its products. Its lead pipeline product candidate, RM-1929, an antibody conjugate of cetuximab and IRDye 700DX, targeting epidermal growth factor receptors (EGFR), which find expression in various types of solid tumors, including cancers of the head and neck, colon, esophagus, lung, pancreas and others. This first-in-class treatment harnesses an antibody conjugate to accurately act against cancer cells by activating the conjugated dye with red light to draw quick anti-cancer responses. Aspyrian Therapeutics is headquartered in San Diego, California, the US.

Aspyrian Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Aspyrian Therapeutics Raises USD15 Million in Series B-1 Financing 10
Aspyrian Therapeutics Raises Additional USD15.2 Million in Series B Venture Financing 11
Aspyrian Therapeutics Raises USD40 Million in Series B Financing Round 12
Aspyrian Therapeutics Raises USD4.25 Million in Extended Series A Financing 13
Aspyrian Therapeutics Raises USD2 Million in Venture Financing 14
Licensing Agreements 15
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 15
Aspyrian Therapeutics Inc – Key Competitors 16
Aspyrian Therapeutics Inc – Key Employees 17
Aspyrian Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Product News 19
04/27/2017: Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options 19
Clinical Trials 20
Jan 16, 2018: Aspyrian Therapeutics announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer 20
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aspyrian Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aspyrian Therapeutics Raises USD15 Million in Series B-1 Financing 10
Aspyrian Therapeutics Raises Additional USD15.2 Million in Series B Venture Financing 11
Aspyrian Therapeutics Raises USD40 Million in Series B Financing Round 12
Aspyrian Therapeutics Raises USD4.25 Million in Extended Series A Financing 13
Aspyrian Therapeutics Raises USD2 Million in Venture Financing 14
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 15
Aspyrian Therapeutics Inc, Key Competitors 16
Aspyrian Therapeutics Inc, Key Employees 17

List of Figures
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3051)販売に関する免責事項を必ずご確認ください。
★調査レポート[Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆